90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia - Trial NCT04856215
Access comprehensive clinical trial information for NCT04856215 through Pure Global AI's free database. This Phase 2 trial is sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Great Ormond Street Hospital for Children NHS Foundation Trust
Timeline & Enrollment
Phase 2
Jan 01, 2022
Jun 01, 2024
Primary Outcome
Disease response after [90Y]-labelled anti-CD66 monoclonal antibody
Summary
Children affected by high risk or relapsed/refractory leukaemia have a poor prognosis, with
 an increased risk of relapse. These patients generally need treatment intensification and a
 bone marrow transplantation (BMT).
 
 Nevertheless, with conventional treatent the risk of relapse after transplant remains high.
 
 Radioimmunotherapy provides a way to deliver high dose irradiation to the bone marrow (where
 leukaemia resides), while sparing normal organs and tissues from its toxicity.This can be
 achieved by linking a radioactive molecule (Yttrium90) to an antibody that, once infused in
 the blood, targets marrow/leukemic cells.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04856215
Non-Device Trial